M0 Space and The SPARTAN Trial
Eric J. Small, MD, FASCO, presented “M0 Space and The SPARTAN Trial,” followed by a discussion with E. David Crawford, MD.
How to cite: Small, Eric J. “M0 Space and The SPARTAN Trial” April 18, 2018. Accessed [date today]. https://dev.grandroundsinurology.com/m0-space-and-the-spartan-trial/
M0 Space and The SPARTAN Trial
Summary:
Eric J. Small, MD, FASCO, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.
Following this overview, Dr. Small answers questions from E. David Crawford, MD.
ABOUT THE AUTHOR
Dr. Eric J. Small is a Professor of Medicine and Urology at the University of California, San Francisco (UCSF) He is also Chief of the Division of Hematology/Oncology in the Department of Medicine of UCSF, as well as UCSF Deputy Director and Chief Scientific Officer and Program Leader of the Prostate Cancer Program there. His patient care and research focus is prostate cancer, immunotherapy, and the mechanisms of resistance to standard therapies. He is a member of several professional medical societies, including the American Society of Clinical Oncology and the American Urological Association. He is a member of the Therapy Consortium of CaP CURE, the largest private source of prostate cancer research funding, and is on the Board of Directors of the American Prostate Cancer Foundation. He chairs the Prostate Cancer Correlative Sciences Working Group of the Cancer and Leukemia Group B Cooperative Oncology Group.
Small earned a bachelor’s degree at Stanford University and a medical degree at Case Western Reserve University School of Medicine, where he graduated with honors. While in medical school, he completed a Fellowship in Pathology. He completed postgraduate residency training in internal medicine at Beth Israel Hospital and a Fellowship in Hematology and Oncology at the UCSF Cancer Research Institute.
